Skip to main content
. 2019 Feb 21;474(5):577–584. doi: 10.1007/s00428-019-02540-w

Table 5.

Results by case in Tests 1 and 2. Percent exactly correct and correct or acceptable replies in percent and number

Test 1 Test 2
Case Diagnosis % correct (95% CI) % correct or acceptable (95% CI) % correct (95% CI) % correct or acceptable (95% CI)
1 Adenosis 26.3 (20.7–32.6) 79.5 (73.6–84.6) 50.0 (43.3–56.7) 89.3 (84.5–93.0)
2 Cancer 36.6 (30.3–43.3) 36.6 (30.3–43.3) 52.2 (45.5–58.9) 52.2 (45.5–58.9)
3 Partial atrophy 27.2 (21.5–33.6) 78.6 (72.6–83.8) 24.6 (19.1–30.7) 77.2 (71.2–82.6)
4 Cancer 27.7 (21.9–34.0) 27.7 (21.9–34.0) 57.1 (50.4–63.7) 57.1 (50.4–63.7)
5 Postatrophic hyperplasia 27.7 (21.9–34.0) 67.4 (60.8–73.5) 45.1 (38.5–51.9) 75.0 (68.8–80.5)
6 Clear cell cribriform hyperplasia 55.4 (48.6–62.0) 86.2 (80.9–90.4) 61.6 (54.9–68.0) 91.5 (87.1–94.8)
7 Seminal vesicle 61.2 (54.4–67.6) 69.6 (63.2–75.6) 92.9 (88.7–95.9) 95.5 (91.9–97.8)
8 Basal cell hyperplasia 62.9 (56.3–69.3) 72.3 (66.0–78.1) 79.9 (74.1–85.0) 84.8 (79.4–89.3)
9 Partial atrophy 12.5 (8.5–17.6) 70.5 (64.1–76.4) 26.3 (20.7–32.6) 78.6 (72.6–83.8)
10 Cancer 50.9 (44.1–57.6) 50.9 (44.1–57.6) 79.0 (73.1–84.2) 79.0 (73.1–84.2)
11 Partial atrophy 11.2 (7.4–16.0) 71.0 (64.6–76.8) 22.8 (17.4–28.8) 71.9 (65.5–77.7)
12 Postatrophic hyperplasia 25.9 (20.3–32.1) 76.8 (70.7–82.1) 45.1 (38.5–51.9) 83.5 (78.0–88.1)
13 Cancer 21.0 (15.8–26.9) 21.0 (15.8–26.9) 38.4 (32.0–45.1) 38.4 (32.0–45.1)
14 Partial atrophy 7.6 (4.5–11.9) 91.5 (87.1–94.8) 11.6 (7.7–16.5) 89.3 (84.5–93.0)
15 Cancer 17.0 (12.3–22.5) 17.0 (12.3–22.5) 20.5 (15.4–26.4) 20.5 (15.4–26.4)
16 Adenosis 38.4 (32.0–45.1) 54.0 (47.3–60.7) 61.2 (54.4–67.6) 70.5 (64.1–76.4)